Market revenue in 2023 | USD 13.0 million |
Market revenue in 2030 | USD 46.8 million |
Growth rate | 20.1% (CAGR from 2023 to 2030) |
Largest segment | Cell & gene therapy |
Fastest growing segment | Cell & Gene Therapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Cell & Gene Therapy, Immunotherapy |
Key market players worldwide | Charles River Laboratories International Inc, Boehringer Ingelheim, Thermo Fisher Scientific Inc, Lonza Group Ltd, Viva Biotech, VGXI, PlasmidFactory, BioCina, TriLink BioTechnologies, Esco Aster |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to plasmid dna contract manufacturing market will help companies and investors design strategic landscapes.
Cell & gene therapy was the largest segment with a revenue share of 60% in 2023. Horizon Databook has segmented the China plasmid dna contract manufacturing market based on cell & gene therapy, immunotherapy covering the revenue growth of each sub-segment from 2018 to 2030.
The rising popularity of gene therapies among the patients, growing biopharmaceutical industry, and increasing prevalence of the chronic diseases, such as cardiovascular & infectious diseases and cancer, propel growth of the market in the region.
Furthermore, the wide use of pDNA in manufacturing the vaccines also increases the market demand in the country. For instance, according to an article by NIH, in 2019, the Chinese population comprised 18% of the global population with 164.5 million of them being 65 or older and 26.0 million being 80 or older.
With China's aging population, the burden on the country's family and public healthcare systems is also increasing. The management of Chronic Non-Communicable Diseases (CNCDs), physical frailty, neurological disorders, and cardiovascular diseases is a significant challenge for the healthcare system in China.
Horizon Databook provides a detailed overview of country-level data and insights on the China plasmid dna contract manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into China plasmid dna contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account